Sector News

Teva, amid massive restructuring, closes in on $3B cost-cutting goal

May 2, 2019
Life sciences

When Kåre Schultz joined Teva as CEO back in November 2017, the drugmaker was in a world of hurt. It was saddled with debt, costs were high and sales were falling. Now, Teva is in the second year of a two-year cost-cutting campaign, and so far the drugmaker has chopped billions in annual expenses.

As Teva reported first-quarter results, Schultz said the restructuring has “not been an easy exercise.” A lot of “good people”—around 10,000—have already left the company, the CEO said on Thursday’s conference call with analysts. More will leave this year. The restructuring has included site consolidation for both manufacturing and administrative locations.

So far, the company has cut about $2.5 billion in costs out of a $3 billion goal. Teva’s 2017 expenses were $16.3 billion, and management wants to get the figure to $13.3 billion this year.

While the drugmaker pushes ahead with its massive restructuring, Schultz and his exec team had some other updates for investors and analysts Thursday, and some weren’t pretty. For one, the company is guiding for lower Copaxone sales after a rough first quarter.

During the period, multiple sclerosis drug Copaxone continued its freefall under generic pressure and turned in $208 million, down 56% from $476 million during the same period last year. Now, Teva expects U.S. Copaxone sales to come in at $800 million this year, versus prior expectations of $1 billion. Globally, the drug should pull in $1.3 billion in 2019, execs said.

But Copaxone’s sharper-than-expected slide isn’t entirely a bad thing, Schultz said on Thursday’s call, as if putting forth a silver lining. He expects 2019 to be Teva’s “trough year” in earnings and possibly sales, so a lower Copaxone base will make it easier to grow in 2020.

“The faster you get out of it, the easier it is to get away from it,” Schultz said.

Meanwhile, the company has been streamlining its generics portfolio and paring drugs that it used to sell at a loss. Schultz said Teva has seen continued “stabilization” of the business; Teva’s North American generics business is now pulling in about $1 billion per quarter.

While industry watchers have been focusing on struggling areas in the business, Teva had new launches to highlight as well. New migraine med Ajovy and Austedo, a treatment for tardive dyskinesia and chorea associated with Huntington’s disease, are expected to chip in much-needed growth as they gain steam. The company expects the meds to contribute $150 million and $350 million this year, respectively, and grow “substantially” in future years.

But even as Teva presses ahead in migraine prevention with Ajovy, the company won’t be able to grow in cluster headache after pulling its FDA application in the use. The setback gives Eli Lilly’s Emgality the pole position in the indication after its drug scored a priority review.

In all, Teva turned in first-quarter revenues of $4.3 billion, a decrease of 15%. Sales in the U.S. slipped 20% during the first quarter. The company reaffirmed its 2019 guidance after the first-quarter performance.

For his work in the turnaround, Schultz has been compensated handsomely. His $33 million pay package for 2018—his first full year on the job—tops the list for biopharma CEOs based on available proxy filings.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).